Nathan T. Ihle

Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome

Nathan T. Ihle, Lauren A. Byers, Edward S. Kim et al. · JNCI Journal of the National Cancer Institute · 2012 · 529 citations · Full text

Medicine, Genetics, Oncology +17

Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling

Nathan T. Ihle, Ryan Williams, Sherry Chow et al. · Molecular Cancer Therapeutics · 2004 · 312 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +12

Chemical Proteomics Identifies Druggable Vulnerabilities in a Genetically Defined Cancer

Liron Bar‐Peled, Esther K. Kemper, Radu M. Suciu et al. · Cell · 2017 · 288 citations · Full text

Life Sciences, Molecular Biology, Oncology +12

Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance

Nathan T. Ihle, Robert Lemos, Peter Wipf et al. · Cancer Research · 2008 · 274 citations · Full text

Medicine, Oncology, Pharmacology +17

Stability of Phosphoprotein as a Biological Marker of Tumor Signaling

Amanda F. Baker, Tomislav Dragovich, Nathan T. Ihle et al. · Clinical Cancer Research · 2005 · 168 citations

Medicine, Molecular Biology, Oncology +17